PTPN11 and neoplasm: PTPN11/Shp2 is currently being investigated as a novel therapy target in some hematologic malignancies and solid tumours [12,21,22], and recently, Shp2 inhibition was been shown to reduce tumour burden significantly in vivo in a metastatic breast cancer model [23].